Coinfection With Confers Protection Against Cutaneous Leishmaniasis.

Infection with certain bacteria, parasites, and viruses alters the host immune system to influencing disease outcome. Here, we determined the outcome of a chronic infection with on cutaneous leishmaniasis (CL) caused by . C57BL/6 mice infected with were given a sub-curative treatment with diminazene aceturate then coinfected with by vector bites.

A defined subunit vaccine that protects against vector-borne visceral leishmaniasis.

Vaccine development for vector-borne pathogens may be accelerated through the use of relevant challenge models, as has been the case for malaria. Because of the demonstrated biological importance of vector-derived molecules in establishing natural infections, incorporating natural challenge models into vaccine development strategies may increase the accuracy of predicting efficacy under field conditions. Until recently, however, there was no natural challenge model available for the evaluation of vaccine candidates against visceral leishmaniasis.

Leishmania HASP and SHERP Genes Are Required for In Vivo Differentiation, Parasite Transmission and Virulence Attenuation in the Host.

Differentiation of extracellular Leishmania promastigotes within their sand fly vector, termed metacyclogenesis, is considered to be essential for parasites to regain mammalian host infectivity. Metacyclogenesis is accompanied by changes in the local parasite environment, including secretion of complex glycoconjugates within the promastigote secretory gel and colonization and degradation of the sand fly stomodeal valve. Deletion of the stage-regulated HASP and SHERP genes on chromosome 23 of Leishmania major is known to stall metacyclogenesis in the sand fly but not in in vitro culture.